Floatz logo

Lifileucel

Unresectable Ureter Urothelial Carcinoma

Roswell Park Cancer InstituteCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Unresectable Ureter Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Epirubicin
Fred Hutchinson Cancer Center
Phase 2B
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2B
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
ERIBULIN MONOMETHANESULFONATE
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
Roswell Park Cancer Institute
Phase 2CCC
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 1/2CC

Same molecule, other indications

Lifileucel is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →